This glutamine-dependent pathway has recently shown to support the growth of KRAS-transformed pancreatic cancer cells by increasing the ratio of NADPH/NADP+ which attenuates ROS toxicity though maintenance of reduced glutathione [33]. This evidence concerns the gene KRAS and pancreatic neoplasm.